Quinacrine (Generic (historically marketed as Atabrine, though primarily available as generic quinacrine for research use))

Other Medications

EU Not submitted to EMA ES Not funded 1 Clinical Trials

Description

Quinacrine is an antimalarial drug that has been investigated as a potential anti-cancer agent for colorectal cancer through repurposing studies. It shows promise in preclinical research for inhibiting cancer cell growth and inducing apoptosis in colorectal cancer cells.

Mechanism of Action

Quinacrine works by intercalating into DNA, inhibiting topoisomerase II, and disrupting cellular processes including autophagy and apoptosis pathways in cancer cells.

Side Effects

Nausea and vomiting Yellow discoloration of skin and urine Headache and dizziness Gastrointestinal upset

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT01844076 Phase 1
Archived
Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma
United States

Quick Info

Brand NameGeneric (historically marketed as Atabrine, though primarily available as generic quinacrine for research use)
CategoryOther Medications
EU EMA StatusNot submitted to EMA
ES Spain AccessNot funded
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.